Nektar Therapeutics, a clinical-stage biotechnology company specializing in immunotherapy, has announced the filing of a preliminary prospectus supplement with the U.S. Securities and Exchange Commission $(SEC.UK)$ as part of its proposed underwritten public offering. The company plans to offer shares of its common stock and pre-funded warrants to certain investors. Jefferies and Piper Sandler are acting as joint bookrunning managers for the offering. The proceeds are intended for general corporate purposes, including research, development, and manufacturing costs for advancing drug candidates. The offering is subject to market conditions, and Nektar has granted underwriters a 30-day option to purchase an additional 15% of the shares. The offering is made under a shelf registration statement declared effective on April 1, 2025.